Transformative pain therapeutics

Changing the course of pain for patients who need it most

Who we are

Adynxx, located in San Francisco, is a clinical-stage biotechnology company developing a transformative technology platform addressing pain at its molecular roots. Adynxx’s unique approach is to transform pain management by approaching pain as a disease rather than a symptom.

Therapeutic approach

Provide safe, non-opioid, long-term pain reduction with a single administration

Clear mission

Developing transformative, first-in-class therapies to address significant unmet medical needs

Groundbreaking Science

A proprietary platform of non-opioid, disease-modifying oligonucleotide therapeutics

Tackling high unmet need

Focusing on patients who have the greatest need for innovative pain treatments

News & Publications

Nov 15, 2018
SAN FRANCISCO & MOUNTAIN VIEW, Calif.--November 15, 2018--Adynxx, Inc., a clinical-stage biotechnology company focused on pain and inflammation, and twoXAR, Inc., an artificial intelligence (AI)-driven biopharmaceutical company, today announced an agreement to develop an oral, non-hormonal drug therapy with the potential to address the underlying mechanisms of endometriosis and significantly improve upon the standard of care.

Meet our team

Experienced management team with a proven track record of success dedicated to improving the life of patients